Specialty chemicals-maker Lanxess said 2020 sales fell by 10% as the COVID-19 pandemic weakened demand, but the company’s net income jumped after it divested its stake in a chemical park venture in Germany.
“The group’s stable position is standing the test of the crisis,” Matthias Zachert, chairman of Lanxess’ management board, said Thursday.
The Germany-based company operates its North American headquarters in Findlay.
Sales for the year fell to 6.1 billion euros ($7.3 billion) from 6.8 billion euros ($8.1 billion) in 2019.
North American sales, which accounted for 23% of global revenues, fell to 1.4 billion euros ($1.8 billion) from 1.6 billion euros ($1.9 billion) the prior year.
A drop in sales of chemicals and materials used by the automotive, aviation, construction and plastics industries was somewhat offset by sales of consumer protection chemicals including disinfectants used to combat the COVID-19 virus.
Lanxess recently announced three acquisitions in the consumer products segment, including the second-largest deal in its history: the pending purchase of Vancouver, Wash.-based Emerald Kalama Chemical for $1 billion.
Net income soared to 885 million euros ($1.1 billion) from 205 million euros ($246 million) the prior year as a result of Lanxess selling its 40% share of chemical park operator Currenta in April to Macquarie Infrastructure and Real Assets. The business park was previously a joint venture with Bayer.
Earnings before interest, taxes, depreciation and amortization (EBITDA) fell by 15% to 862 million euros ($1.03 billion) at the upper end of Lanxess’ guidance.
For 2021, the company expects earnings to range from 900 million euros to 1 billion euros ($1.08 billion to $1.2 billion).
Lanxess has 14,300 employees worldwide. About 350 work in the Pittsburgh region at the Findlay headquarters and at plants on Neville Island and in Burgettstown.
Joyce Gannon: jgannon@post-gazette.com






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.